A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

NCT04075266 PHASE2 ACTIVE_NOT_RECRUITING Results posted

This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	23
Start date	Thu Jan 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Dec 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Sclerosis

Interventions

• Ocrelizumab

Countries

Italy, United States, Poland